Ranibizumab bei Makuladegeneration. Angiogenese-Hemmung gegen Sehverlust

Saved in:
Bibliographic Details
Published inPharmazie in unserer Zeit Vol. 36; no. 6; pp. 437 - 440
Main Authors Mohr-Andrä, Marion, Mohr, Klaus
Format Journal Article
LanguageGerman
Published Weinheim WILEY-VCH Verlag 01.11.2007
Online AccessGet full text

Cover

Author Mohr-Andrä, Marion
Mohr, Klaus
Author_xml – sequence: 1
  givenname: Marion
  surname: Mohr-Andrä
  fullname: Mohr-Andrä, Marion
  organization: Universität Bonn
– sequence: 2
  givenname: Klaus
  surname: Mohr
  fullname: Mohr, Klaus
  email: k.mohr@uni-bonn.de
  organization: Pharmazeutisches Institut, Gerhard-Domagk-Str. 3, 53121 Bonn
BookMark eNqVikFOwzAQRUeoSKSFLWtfwGFcNw5ZIgRkAxI0AomNNRFDME2cyo4R9PS0Ehdg9fTff3OY-dEzwLnCXCEuL7aUdvkSsdwPXR1Bpowq5P7SM8gQV5dSG7M6gXmMn4hYVVWRQf1E3rVulwZqRctO3NMm9fTGHXsONLnR5-LKd248iMiy5mFIvhPdoRBr_vji0Kc4ncLxO_WRz_64AHl701zX0sWJv-02uIHCj6WwsabUZWFfHu7s66PC5wYba_R_-188HkuP
ContentType Journal Article
DBID BSCLL
DOI 10.1002/pauz.200700239
DatabaseName Istex
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1615-1003
EndPage 440
ExternalDocumentID ark_67375_WNG_ZQ10VT0T_6
GroupedDBID .3N
.GA
.Y3
10A
123
1OC
1ZS
31~
3WU
4.4
51W
51X
52M
52N
52O
52P
52S
52T
52W
52X
53G
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8UM
AAHHS
AAZKR
ABCQN
ABEML
ABIJN
ACBWZ
ACCFJ
ACGFS
ACSCC
ACXQS
AEEZP
AEQDE
AEUCX
AFBPY
AFZJQ
AHMBA
AIWBW
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
BDRZF
BFHJK
BSCLL
BY8
CS3
D-E
D-F
DCZOG
DR2
DU5
EBD
EBS
EJD
F00
F04
F5P
FEDTE
GODZA
HF~
HOLLA
HVGLF
HZ~
IX1
LAW
LC2
LC3
LH4
LP6
LP7
LW6
M6Q
MK4
N9A
OIG
P2P
P2X
P4D
PALCI
PQQKQ
Q11
QB0
QRW
RIWAO
RJQFR
ROL
RX1
RYL
SUPJJ
UB1
W8V
W99
WQJ
WRC
WYUIH
XG1
XV2
YCJ
ID FETCH-istex_primary_ark_67375_WNG_ZQ10VT0T_63
ISSN 0048-3664
IngestDate Wed Oct 30 10:01:12 EDT 2024
IsPeerReviewed false
IsScholarly false
Issue 6
Language German
LinkModel OpenURL
MergedId FETCHMERGED-istex_primary_ark_67375_WNG_ZQ10VT0T_63
Notes ark:/67375/WNG-ZQ10VT0T-6
istex:CD211AD8AEBB538029C05EB8670E3EE956BFE9AF
ArticleID:PAUZ200700239
ParticipantIDs istex_primary_ark_67375_WNG_ZQ10VT0T_6
PublicationCentury 2000
PublicationDate 2007-11
PublicationDateYYYYMMDD 2007-11-01
PublicationDate_xml – month: 11
  year: 2007
  text: 2007-11
PublicationDecade 2000
PublicationPlace Weinheim
PublicationPlace_xml – name: Weinheim
PublicationTitle Pharmazie in unserer Zeit
PublicationTitleAlternate Pharmazie in unserer Zeit
PublicationYear 2007
Publisher WILEY-VCH Verlag
Publisher_xml – name: WILEY-VCH Verlag
References Bashshur, Z.F. et al., Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration. Am. J. Ophthalmol. 142, (2006), 1-9.
Brown, D.M. et al., Ranibizumab versus Verteporfin for Neovascular Age-related Macular Degeneration (ANCHOR Study Group). N. Engl. J. Med. 355, (2006), 1432-1444.
Rosenfeld, P.J. et al., Ranibizumab for Neovascular Age-related Macular Degeneration (MARINA Study Group). N. Engl. J. Med. 355, (2006), 1419-1431.
Gragoudas, E.S. et al., Pegaptanib for Neovascular Age-related Macular Degeneration (VISION Study Group). N. Engl. J. Med. 351, (2004), 2805-2816.
Steinbrook, R., The price of Sight - Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration. N. Engl. J. Med. 355, (2006), 1409-1412.
Joussen, A.M., Molekulare Pathogenese vaskulärer Erkrankungen des Auges - Antiangiogenese als Therapiekonzept. Dtsch. Med. Wochenschr. 132, (2007), 1268-1272.
References_xml
SSID ssj0009995
Score 2.794188
SourceID istex
SourceType Publisher
StartPage 437
Title Ranibizumab bei Makuladegeneration. Angiogenese-Hemmung gegen Sehverlust
URI https://api.istex.fr/ark:/67375/WNG-ZQ10VT0T-6/fulltext.pdf
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT8IwGG28vPhivMZ7-mB4mcWxlTEejVEXEwiaiYSXpdsKLCCQwRLl1_u1nWwiJujLsjTNtu47O_16OWcIXVYZ5KB2GBBTNzqEBgElVd8yCIxvS6zjl3xTF9rhWt1yXuhjq9zKprKlumTqF4PZUl3Jf6IKZRBXoZL9Q2TnF4UCOIf4whEiDMeVYvzMhpEfzZI35ms-j7Qa6ycDFvKu9JIW9y1qN8NuNBIFE04cLtQgXa0ragBN9KDFg2TybXq-Ib2sZ5E0ExF69ZjHWptH8-0xtVEvJmIfpFxjp6ngJ7ecLypI_hiwhVmFSiqvm3OX_MdV89bRctOKKYVSm5iWsh4vcsWakBYBn-tmnlaVr0kKnzxHUuXykna3VLk1_WBy5Qw7ZslM2gVIEW7WZ32t0y90ZfMNhizuix1rlbL3Wn_w2k8lvenqrmeto00DGEmu5z9nPmOQJatfXaRt-3L31I3r708AQxjx9b3nchB3B22ngwd8o5Cwi9ZCvocKKmLBxxV2MzHd5AoXcCPzJf_YR04OLhjggpfABS-BC5ZwwRlcDhC5v3NvHSIf0hsrwxLvt7dhHqKN4WjIjxBmVIeP2axy2w5pmTFmGSGvUlrplANmMvsYFVa75smqFU_RVga8M7QxjRN-Dgne1L-QwfkEOXFX1A
link.rule.ids 315,783,787,27936,27937
linkProvider Wiley-Blackwell
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ranibizumab+bei+Makuladegeneration.+Angiogenese-Hemmung+gegen+Sehverlust&rft.jtitle=Pharmazie+in+unserer+Zeit&rft.au=Mohr-Andr%C3%A4%2C+Marion&rft.au=Mohr%2C+Klaus&rft.date=2007-11-01&rft.pub=WILEY-VCH+Verlag&rft.issn=0048-3664&rft.eissn=1615-1003&rft.volume=36&rft.issue=6&rft.spage=437&rft.epage=440&rft_id=info:doi/10.1002%2Fpauz.200700239&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_ZQ10VT0T_6
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0048-3664&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0048-3664&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0048-3664&client=summon